Distinctive phenogroup to differentiate diagnosis of cardiac myxoma vs cardiovascular disease examining blood-based circulating cell biomarkers.

Autor: Donato G; Department of Health Sciences, University 'Magna Graecia', 88100, Catanzaro, Italy., Mignogna C; Interdipartimentale Service Center, University Magna Graecia, Catanzaro, Italy., Santise G; Cardiothoracic Surgery Unit, Sant'Anna Hospital, Via Pio X, 111, Catanzaro, Italy., Presta I; Department of Health Sciences, University 'Magna Graecia', 88100, Catanzaro, Italy., Ferrazzo T; Department of Health Sciences, University 'Magna Graecia', 88100, Catanzaro, Italy., Garo V; Department of Health Sciences, University 'Magna Graecia', 88100, Catanzaro, Italy., Maselli D; Cardiothoracic Surgery Unit, Sant'Anna Hospital, Via Pio X, 111, Catanzaro, Italy., Curcio A; Department of Medical and Surgical Sciences, University Magna Graecia, Catanzaro, Italy., De Rosa S; Department of Medical and Surgical Sciences, University Magna Graecia, Catanzaro, Italy., Spaccarotella C; Department of Medical and Surgical Sciences, University Magna Graecia, Catanzaro, Italy., Mollace V; Department of Health Sciences, University 'Magna Graecia', 88100, Catanzaro, Italy., Gentile F; Department of Experimental and Clinical Medicine, University Magna Graecia, Catanzaro, Italy., Indolfi C; Department of Medical and Surgical Sciences, University Magna Graecia, Catanzaro, Italy., Malara N; Department of Health Sciences, University 'Magna Graecia', 88100, Catanzaro, Italy. nataliamalara@unicz.it.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2023 Nov 21; Vol. 13 (1), pp. 20357. Date of Electronic Publication: 2023 Nov 21.
DOI: 10.1038/s41598-023-47639-y
Abstrakt: Cardiac myxoma (CM) is a potentially life-threatening disease because frequently asymptomatic or debuts with aspecific manifestations. Definitive diagnosis is established by histopathological assessment including tumor and endothelial cell markers. To derive a specific panel of circulating cells antigenically detectable, pre-surgery peripheral blood samples of CM patients were analyzed. Pre-surgery peripheral blood samples from patients with CM were simultaneously analyzed for Circulating tumor cells (CTCs) and circulating endothelial cells (CECs) that were matched with tumor tissue profiles and with patient-derived xenografts (PDXs) distinguishing tumor regions. Moreover, CECs values in CM patients were further matched with CEC's levels in cardiovascular disease and control subjects. The blood-derived cytological specimens detected at least 1-3 CTCs/ml in 10 tested CM samples (p = 0.0001) showing specific CM features preserved in the central zones of the tumor. The central zone of the primary tumor, supported by a vessel density rate (55 ± 7%), with a proliferative profile of 32 ± 3% and a percentage of Calretinin pos cells (p = 0.03), is the principal site of CTCs (r = 00) dissemination. The subsets of endothelial cells recognized in the blood were indifferent to their topological distribution within the tumor and corresponding PDXs. With further refinement and validation in large cohorts, multiparametric liquid biopsies can optimally integrate clinically informative datasets and maximize their utility in pre-surgery evaluation of CM patients. Blood-derived culture's protocol provides a versatile method capable of viable analysis of CTCs of non-hematological rare tumors which conventional antibody-mediated analytical platform is unable to perform. Distinctive blood- based cell phenotype contributes to differentiate CM from other differentials assuring its prompt surgical resection by combining blood-based cell biomarkers integrated with clinically informative datasets.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje